Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced that it has received marketing approval for Tyvyt (sintilimab injection), a PD-1 inhibitor co-developed with US pharmaceutical giant Eli Lilly, for multiple indications in Macau. The drug has been approved to treat classic Hodgkin’s lymphoma (cHL), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and adenocarcinoma of the stomach and gastroesophageal junction (GC/GEJ).
In mainland China, sintilimab has been approved for seven indications since December 2018, all of which are included in the National Reimbursement Drug List (NRDL). These indications cover a range of cancers, including recurrent or refractory cHL, first-line treatment of locally advanced or metastatic NSCLC with negative mutations in the epidermal growth factor receptor (EGFR) gene and negative anaplastic lymphoma kinase (ALK), locally advanced or metastatic NSCLC in patients with EGFR-positive gene mutations who have failed treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), first-line treatment of locally advanced or metastatic squamous NSCLC, first-line treatment of unresectable or metastatic HCC, first-line treatment of unresectable locally advanced, recurrent or metastatic ESCC, and first-line treatment of unresectable locally advanced, recurrent or metastatic GC/GEJ.
The approval of Tyvyt in Macau further expands the reach of this innovative therapy, providing more patients with access to a potentially life-changing treatment option.- Flcube.com
